Eribulin Mesylate .5 mg/mL (Eribulin Mesylate INJECTION) .5 mg/mL

Eribulin Mesylate .5 mg/mL is an injectable medication used for specific therapeutic purposes. This single-dose vial is designed for intravenous administration and is manufactured by Baxter Healthcare Company in the USA.

Strength

.5 mg/mL

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (10019-080-01) / 2 mL in 1 VIAL, SINGLE-DOSE

Manufacturer / TM Owner

Baxter Healthcare Company

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Eribulin Mesylate is primarily used in the treatment of certain types of cancer. It works by targeting cancer cells to inhibit their growth and spread. Patients often wonder, 'What is Eribulin Mesylate used for?' It is typically prescribed for advanced stages of cancer where other treatments have not been effective.

Side Effects

Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may also experience peripheral neuropathy, which is a tingling or numbness in the hands and feet. These effects can vary from person to person and should be discussed with a healthcare provider.

Precautions & Warnings

Eribulin Mesylate should be handled with care, as it is a potent medication. It is important to follow proper storage and administration guidelines to ensure safety. Patients should inform their healthcare provider about any allergies or medical conditions before starting treatment.

Avoid Interactions

Eribulin Mesylate may interact with other medications, including those that affect liver function or blood cell production. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of Eribulin Mesylate.

Frequently Asked Questions

Eribulin Mesylate is used in the treatment of certain types of cancer, particularly in advanced stages where other treatments have not been effective.

Eribulin Mesylate is administered intravenously, typically in a clinical setting by a healthcare professional.

Common side effects may include fatigue, nausea, hair loss, and peripheral neuropathy.

Eribulin Mesylate may interact with other medications, so it is important to discuss all current medications with a healthcare provider.

Eribulin Mesylate should be stored according to the manufacturer's guidelines to maintain its efficacy and safety.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.